Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14979208 | 0.88 | L3MBTL1 (0.52) | CYP1A2CYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL14979170 | 0.87 | NR1H4 (0.56) | PTGDR2KMT2AMEN1NR1H4NPC1 | |
| SCHEMBL16085966 | 0.86 | PTGDR2 (0.59) | PTGDR2KMT2AMEN1NR1H4CA12 | |
| SCHEMBL14979228 | 0.81 | KMT2A (0.47) | CYP1A2CYP3A4CYP2C19PTGDR2KMT2A | |
| SCHEMBL14979204 | 0.80 | PTGDR2 (0.48) | PTGDR2KMT2AMEN1NR1H4CA12 | |
| SCHEMBL14979245 | 0.80 | PTGDR2 (0.51) | PTGDR2 | |
| SCHEMBL16087764 | 0.79 | NR1H4 (0.51) | PTGDR2KMT2AMEN1NR1H4NPC1 | |
| SCHEMBL14979241 | 0.78 | PTGDR2 (0.46) | PTGDR2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL16153712 | 0.78 | NR1H4 (0.52) | PTGDR2KMT2AMEN1NR1H4NPC1 | |
| SCHEMBL14979210 | 0.78 | L3MBTL1 (0.64) | CYP1A2CYP3A4CYP2C9CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2781508-B9 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-2781508-B1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2018-12-12 | — | — | EP | disclosed |
| US-9233098-B2 | Nitrogen-containing fused ring compounds as CRTH2 antagonists | KBP BIOSCIENCES CO., LTD. (CN) | 2016-01-12 | — | — | US | disclosed |
| US-9233098-B2 | Nitrogen-containing fused ring compounds as CRTH2 antagonists | KBP BIOSCIENCES CO., LTD. (CN) | 2016-01-12 | — | — | US | disclosed |
| US-9233098-B2 | Nitrogen-containing fused ring compounds as CRTH2 antagonists | KBP BIOSCIENCES CO., LTD. (CN) | 2016-01-12 | — | — | US | disclosed |
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO., LTD. (CN) | 2014-10-09 | — | — | US | disclosed |
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO., LTD. (CN) | 2014-10-09 | — | — | US | disclosed |
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO., LTD. (CN) | 2014-10-09 | — | — | US | disclosed |
| EP-2781508-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP Biosciences Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013071880-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | 山东亨利医药科技有限责任公司 (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, HRH1, NR3C2 | CYP1A2 1983/4885CYP3A4 3229/4885CYP2C9 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.